Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1999-06-24
2002-04-16
Kunz, Gary L. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C530S387100, C530S387300, C530S389100, C530S350000
Reexamination Certificate
active
06372891
ABSTRACT:
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a human 7-transmembrane receptor. The transmembrane receptor is a G-protein coupled receptor. More particularly, the 7-transmembrane receptor has been putatively identified as a prostate tissue receptor, sometimes hereinafter referred to as “HPRAJ70”. The invention also relates to inhibiting the action of such polypeptides.
It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers, e.g., cAMP (Lefkowitz,
Nature,
351:353-354 (1991)). Herein these proteins are referred to as proteins participating in pathways with G-proteins or PPG proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka et al.,
PNAS,
84:46-50 (1987); Kobilka et al.,
Science,
238:650-656 (1987); Bunzow et al.,
Nature,
336:783-787 (1988)), G-proteins themselves, effector proteins, e.g., phospholipase C, adenyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon et al.,
Science,
252:802-8 (1991)).
For example, in one form of signal transduction, the effect of hormone binding is activation of an enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP, and GTP also influences hormone binding. A G-protein connects the hormone receptors to adenylate cyclase. G-protein was shown to exchange GTP for bound GDP when activated by hormone receptors. The GTP-carrying form then binds to an activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.
G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al.,
Endoc., Rev.,
10:317-331 (1989)). Different G-protein &agr;-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of G-protein coupled receptors have been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupled receptors. G-protein coupled receptors are found in numerous sites within a mammalian host.
In accordance with one aspect of the present invention, there are provided novel polypeptides as well as biologically active and diagnostically or therapeutically useful fragments and derivatives thereof. The polypeptides of the present invention are of human origin.
In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding the polypeptide of the present invention including mRNAs, DNAs, cDNAs, genomic DNA as well as antisense analogs thereof and biologically active and diagnostically or therapeutically useful fragments thereof.
In accordance with a further aspect of the present invention, there is provided a process for producing such polypeptides by recombinant techniques which comprises culturing recombinant prokaryotic and/or eukaryotic host cells, containing a nucleic acid sequence encoding a polypeptide of the present invention, under conditions promoting expression of said polypeptide and subsequent recovery of said polypeptide.
In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.
In accordance with another aspect of the present invention there are provided methods of screening for compounds which bind to and activate or inhibit activation of the receptor polypeptides of the present invention and for receptor ligands.
In accordance with still another embodiment of the present invention there is provided a process of using such activating compounds to stimulate the receptor polypeptide of the present invention for the treatment of conditions related to the under-expression of the G-protein coupled receptors.
In accordance with another aspect of the present invention there is provided a process of using such inhibiting compounds for treating prostatic cancer and other conditions associated with over-expression of the G-Protein receptor polypeptide.
In accordance with yet another aspect of the present invention there is provided non-naturally occurring synthetic, isolated and/or recombinant polypeptides which are fragments, consensus fragments and/or sequences having conservative amino acid substitutions, of at least one transmembrane domain of the G-protein coupled receptor of the present invention, such that the receptor may bind G-protein coupled receptor ligands, or which may also modulate, quantitatively or qualitatively, G-protein coupled receptor ligand binding.
In accordance with still another aspect of the present invention there are provided synthetic or recombinant G-protein coupled receptor polypeptides, conservative substitution and derivatives thereof, antibodies, anti-idiotype antibodies, compositions and methods that can be useful as potential modulators of G-protein coupled receptor function, by binding to ligands or modulating ligand binding, due to their expected biological properties, which may be used in diagnostic, therapeutic and/or research applications.
It is still another object of the present invention to provide synthetic, isolated or recombinant polypeptides which are designed to inhibit or mimic various G-protein coupled receptors or fragments thereof, as receptor types and subtypes.
In accordance with yet a further aspect of the present invention, there is also provided diagnostic probes comprising nucleic acid molecules of sufficient length to specifically hybridize to the nucleic acid sequences of the present invention.
In accordance with yet another object of the present invention, there is provided a diagnostic assay for detecting a disease or susceptibility to a disease related to a mutation in a nucleic acid sequence of the present invention.
These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.
REFERENCES:
patent: WO 92/17585 (1992-10-01), None
Bowie et al. Science 247:1306-1310), 1990.*
Skolnick et al., Trends in Biotech 18(1): 34-39, Jan. 2000.*
Lee, N. H. et al., Drugs & Perspectives, vol. 6(7):488-497 (1993).
Oliveira L. et al., J. Computer-Aided Molecular Design, vol. 7(6):649-658 (1993).
European Search Report (EP 95 92 1605) (1999).
Ross P.C. et al., Proc. Natl. Acad. Sci., vol. 87:3052-3056 (1990).
Libert F. et al., Science, vol. 244:568-572(1989).
Eva C., et al., FEBS Letter, vol. 271:81-84 (1990).
Buck and Axel, Cell 65(1): 175-187 (1991).
Hla et al., The Journal of Biological Chemistry 265(16): 9308-9316 (1990).
Linda L. Zu, et al., “PSGR, a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor, Is Overexpressed in Prostate Cancer,”Cancer Research,60: 6568-6572 (2000).
Shelagh Wilson, et al., “Orphan G-protein-coupled receptors: the next generation of drug targets?”,British Journal of Pharmacology125: 1387-1392 (1998).
Julie A. Pitcher, et al., “G Protein—Coupled Receptor Kinases,”Annu. Rev. Biochem.67: 653-92 (1998).
Jeffrey M. Stadel, et al., “Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery,”TiPS18: 430-437 (1997).
Stephen W. Edwards, et al., “Localization of G-protein-coupled receptors in health and disease,”TiPS21: 304-308 (2000).
Rennolds S. Ostrom, et al., “Stoichiometry and Compartmentation in G Protein-Coupled Receptor Signaling: Implications for Therapeutic Interventions Involving GS1”,The J
Li Yi
Rosen Craig A.
Ruben Steven M.
Soppet Daniel R.
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Kunz Gary L.
Lazar-Wesley Eliane
LandOfFree
Human G-protein receptor HPRAJ70 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human G-protein receptor HPRAJ70, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human G-protein receptor HPRAJ70 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2822666